Next Century Growth Investors LLC Has $1.15 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Next Century Growth Investors LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,698 shares of the medical device company’s stock after selling 106 shares during the quarter. Next Century Growth Investors LLC’s holdings in DexCom were worth $1,152,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Ossiam lifted its position in DexCom by 4.0% during the 2nd quarter. Ossiam now owns 7,754 shares of the medical device company’s stock worth $3,997,000 after buying an additional 299 shares in the last quarter. Natixis Investment Managers International lifted its position in DexCom by 35.8% during the 2nd quarter. Natixis Investment Managers International now owns 550 shares of the medical device company’s stock worth $234,000 after buying an additional 145 shares in the last quarter. Natixis raised its holdings in shares of DexCom by 104.4% in the 2nd quarter. Natixis now owns 76,297 shares of the medical device company’s stock valued at $32,579,000 after purchasing an additional 38,964 shares during the period. Toroso Investments LLC raised its holdings in shares of DexCom by 55.4% in the 2nd quarter. Toroso Investments LLC now owns 2,055 shares of the medical device company’s stock valued at $877,000 after purchasing an additional 733 shares during the period. Finally, APG Asset Management N.V. raised its holdings in shares of DexCom by 11.3% in the 2nd quarter. APG Asset Management N.V. now owns 17,904 shares of the medical device company’s stock valued at $6,447,000 after purchasing an additional 1,820 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Mark G. Foletta sold 500 shares of the firm’s stock in a transaction on Friday, October 1st. The shares were sold at an average price of $543.09, for a total transaction of $271,545.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew K. Balo sold 2,757 shares of the firm’s stock in a transaction on Tuesday, August 3rd. The shares were sold at an average price of $515.87, for a total transaction of $1,422,253.59. The disclosure for this sale can be found here. Insiders have sold 43,766 shares of company stock valued at $22,883,487 in the last ninety days. Insiders own 0.52% of the company’s stock.

A number of brokerages have recently issued reports on DXCM. Stephens upped their target price on shares of DexCom from $468.00 to $546.00 and gave the company an “overweight” rating in a report on Friday, July 30th. Oppenheimer upped their target price on shares of DexCom from $500.00 to $525.00 and gave the company an “outperform” rating in a report on Friday, July 30th. Morgan Stanley increased their price target on shares of DexCom from $410.00 to $510.00 and gave the company an “equal weight” rating in a report on Monday, August 2nd. Wells Fargo & Company increased their price target on shares of DexCom from $380.00 to $475.00 and gave the company an “equal weight” rating in a report on Friday, July 30th. Finally, Robert W. Baird increased their price target on shares of DexCom from $460.00 to $520.00 and gave the company an “outperform” rating in a report on Friday, July 30th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $515.13.

Shares of NASDAQ DXCM traded up $10.89 during trading hours on Thursday, hitting $558.94. 7,105 shares of the stock were exchanged, compared to its average volume of 743,023. The company has a debt-to-equity ratio of 0.86, a quick ratio of 5.25 and a current ratio of 5.78. The company has a market cap of $54.08 billion, a PE ratio of 104.39, a price-to-earnings-growth ratio of 14.59 and a beta of 0.77. The company’s fifty day simple moving average is $533.80 and its two-hundred day simple moving average is $448.21. DexCom, Inc. has a 1-year low of $305.63 and a 1-year high of $579.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 29th. The medical device company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.33. The firm had revenue of $595.10 million for the quarter, compared to analyst estimates of $548.02 million. DexCom had a net margin of 24.45% and a return on equity of 16.17%. As a group, sell-side analysts expect that DexCom, Inc. will post 2.46 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Recommended Story: What is dividend yield?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.